Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells

SIMPLE SUMMARY: The ToGA trial has demonstrated, in HER2-expressing patients, that unresectable and advanced gastric cancer, chemotherapy and trastuzumab in combination increase overall survival, even if it is still unclear why after one year the same patients are non-responsive to trastuzumab treat...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Laterza, Maria Maddalena, Ciaramella, Vincenza, Facchini, Bianca Arianna, Franzese, Elisena, Liguori, Carmela, De Falco, Stefano, Coppola, Paola, Pompella, Luca, Tirino, Giuseppe, Berretta, Massimiliano, Montella, Liliana, Facchini, Gaetano, Ciardiello, Fortunato, de Vita, Ferdinando
Format: Artigo
Language:Inglês
Published: MDPI 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8150287/
https://ncbi.nlm.nih.gov/pubmed/34066144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102339
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items